Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Non-Current Debt over the past 8 years, most recently at $34.2 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $34.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $34.2 million (changed N/A YoY), and the annual figure for FY2025 was $34.2 million, changed.
  • Non-Current Debt for Q4 2025 was $34.2 million at Viridian Therapeutics, Inc.\DE, up from $20.9 million in the prior quarter.
  • Over the last five years, Non-Current Debt for VRDN hit a ceiling of $34.2 million in Q4 2025 and a floor of $12.4 million in Q2 2025.
  • Median Non-Current Debt over the past 3 years was $20.5 million (2024), compared with a mean of $20.9 million.
  • Peak annual rise in Non-Current Debt hit 1.79% in 2025, while the deepest fall reached 29.36% in 2025.
  • Viridian Therapeutics, Inc.\DE's Non-Current Debt stood at $20.2 million in 2023, then grew by 1.57% to $20.5 million in 2024, then skyrocketed by 66.86% to $34.2 million in 2025.
  • The last three reported values for Non-Current Debt were $34.2 million (Q4 2025), $20.9 million (Q3 2025), and $12.4 million (Q2 2025) per Business Quant data.